FBRX Forte Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FBRX

Price (delayed)

$31.67

Market cap

$427.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.29

Enterprise value

$373.15M

Sector: Healthcare
Industry: Biotechnology
Website: https://tocagen.com

Highlights

Forte Biosciences's debt has plunged by 100% YoY
FBRX's EPS is down by 47% QoQ
FBRX's quick ratio is down by 11% since the previous quarter

Key stats

What are the main financial stats of FBRX
Market
Shares outstanding
13.51M
Market cap
$427.92M
Enterprise value
$373.15M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.82
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$49.24M
EBITDA
-$49.23M
Free cash flow
-$15.38M
Per share
EPS
-$9.29
Free cash flow per share
-$1.16
Book value per share
$4.05
Revenue per share
$0
TBVPS
$4.31
Balance sheet
Total assets
$57.07M
Total liabilities
$2.37M
Debt
$0
Equity
$54.7M
Working capital
$53.5M
Liquidity
Debt to equity
0
Current ratio
23.57
Quick ratio
23.11
Net debt/EBITDA
1.11
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-116.3%
Return on equity
-124%
Return on invested capital
N/A
Return on capital employed
-90%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FBRX stock price

How has the Forte Biosciences stock price performed over time
Intraday
0.19%
1 week
-0.25%
1 month
-13.94%
1 year
78.93%
YTD
-13.02%
QTD
-7.59%

Financial performance

How have Forte Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$49M
Net income
-$49.24M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 6% from the previous quarter
The net income has contracted by 6% from the previous quarter

Growth

What is Forte Biosciences's growth rate over time

Valuation

What is Forte Biosciences stock price valuation
P/E
N/A
P/B
7.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
FBRX's EPS is down by 47% QoQ
The price to book (P/B) is 29% lower than the last 4 quarters average of 11.0
The equity has contracted by 7% from the previous quarter

Efficiency

How efficient is Forte Biosciences business performance
FBRX's return on equity is up by 29% since the previous quarter
The company's return on assets rose by 18% QoQ

Dividends

What is FBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FBRX.

Financial health

How did Forte Biosciences financials performed over time
The company's total liabilities has shrunk by 86% YoY but it rose by 4.9% QoQ
FBRX's quick ratio is down by 11% since the previous quarter
Forte Biosciences's debt is 100% less than its equity
Forte Biosciences's debt has plunged by 100% YoY
The debt to equity has dropped by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.